Psyence Australia Pty Ltd

Psyence Australia Pty Ltd is the Australian subsidiary of Psyence Biomed Ltd (Nasdaq: PBM), a company focused on nature-derived botanical psilocybin medicine; it received HREC approval to conduct a Phase IIb randomized double-blind trial evaluating natural psilocybin (NPX-5 at 10 mg and 25 mg) versus an active low-dose comparator for adjustment disorder in palliative care cancer patients, with sites in Melbourne and Perth.